Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06911203
PHASE2
A Study of BGM0504 in Participants With Obesity
Sponsor: BrightGene Bio-Medical Technology Co., Ltd.
View on ClinicalTrials.gov
Summary
To evaluate the efficacy and safety of BGM0504 compared with Tirzepatide in adult participants who have obesity without diabetes after 26 weeks of treatment.
Official title: A Phase II, Randomized Open-label, Multicenter Study to Evaluate the Efficacy and Safety of BGM0504 Compared to Tirzepatide in Adults Who Have Obesity
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2025-04-03
Completion Date
2026-01-11
Last Updated
2025-10-28
Healthy Volunteers
No
Conditions
Interventions
DRUG
BGM0504
Administered SC
DRUG
Tirzepatide
Administered SC
Locations (1)
Peking University People's Hospital
Beijing, Beijing Municipality, China